Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix completed enrollment of 350 patients in its Phase 3 BiPASS study, evaluating Illuccix and Gozellix for prostate cancer imaging prior to biopsy. The company has aligned with the FDA on an NDA pathway for BiPASS, which if approved, would support new product reimbursement and broaden patient access.
Key figures
- Drug Name
- Illuccix® (gallium Ga 68 gozetotide injection), Gozellix® (gallium Ga 68 gozetotide injection)
- Phase Of Trial
- Phase 3
- Patients enrolled
- 350
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.